Abnormal regulation of gene expression is essential for tumorigenesis. Recent studies indicate that regulation of oncogene expression and neoplastic transformation are controlled by subunits of eukaryotic translation initiation factors (eIFs). Here we focused on eIF3 performing a pivotal role in protein synthesis and the differential expression of its subunits in cancer. The most uncharacterized non-core subunit eIF3m was confirmed to be highly expressed in human cancer cell lines and colon cancer patient tissues. By expression silencing with eIF3m-specific small interfering RNA (siRNA), we confirmed that eIF3m influences cell proliferation, cell cycle progression and cell death in human colon cancer cell line HCT-116. Using a ribonomics approach, we identified a subset of elF3m-influenced genes and showed that the expression of two highly represented tumorigenesis-related genes, MIF and MT2, were affected by eIF3m at the mRNA level. We also confirmed eIF3m-dependent regulation of MT2A downstream molecule CDC25A, which is necessary for cell cycle progression in HCT-116 cells. These results suggest that eIF3m mediates regulation of tumorigenesis-related genes in human colon cancer. Further investigations on tumorigenesis-related genes and their regulation by eIFs will provide clues for designing targeted therapy for cancer.
Introduction
Development of neoplasm is characterized by increased cell proliferation, which requires a general increase in protein synthesis and a specific increase in the synthesis of replication-promoting proteins (Rosenwald, 2004) . Expression of each gene depends on the abundance of its mRNA, but the flow of information from gene to protein in eukaryotes is not immediate enough to comply with rapid changes in the environment. Eukaryotes solve this problem by maintaining a pool of mRNAs that are not utilized currently (De Benedetti and Graff, 2004) . In metazoans, translational efficiency varies over a hundred fold (Koch et al., 1980) and their translation depends on the prevailing growth conditions. According to the ribosome filter hypothesis, the translation initiation factors recruit certain sets of mRNA species to the ribosome and fulfill the requirements for cell proliferation without causing a drastic shift in the existing mRNA pool (Mauro and Edelman, 2002) .
Eukaryotic translation initiation factor 3 (eIF3) is the largest (B800 kDa) and the most complex mammalian initiation factor. elF3 has a pivotal role in protein synthesis that bridges the 43S pre-initiation complex and eIF4F-bound mRNA (Silvera et al., 2010) . It is composed of 13 non-identical polypeptides designated as eIF3a-m (Zhou et al., 2005) . Five of the subunits (eIF3 a, b, c, g and i) are conserved in all eukaryotes (hence called conserved 'core') and the remaining eight are considered 'non-core ' (LeFebvre et al., 2006) . The functional roles of individual subunits are not yet known, but aberrant expression of several eIF3 subunits were detected in various human cancers and reviewed (Dong and Zhang, 2006) . For example, eIF3a is overexpressed in human breast, esophagus, cervix, lung, stomach and colon cancers; eIF3b in human breast cancers; eIF3c in human testicular cancer; eIF3h in breast, liver, and prostate cancers; and eIF3i in breast cancer. Elevated expression of eIF3i in breast cancer was suggested to facilitate mTOR-dependent growth transformation (Ahlemann et al., 2006) . eIF3e, also called INT6 and originally known as a tumor suppressor (Green et al., 2007) and shown to be expressed in a truncated form in tumors, was intensively investigated (Mack et al., 2007) and has been implicated in tumor progression (Morris et al., 2007) . eIF3f was reported to be lost in melanoma and pancreatic cancer (Doldan et al., 2008) . Recently, it was reported that the overexpression of eIF3 subunits leads to malignant transformation of immortal fibroblast cells (Zhang et al., 2007) . Thus far, there have been no reports of altered expression of any of the other eIF3 subunits in cancer and whether these eIF3 subunits are involved in tumorigenesis is not known. Especially, as the last defined eIF3 subunit, the function of eIF3m in humans is not yet characterized.
We hypothesized that the non-core subunit eIF3m may be involved in the process of cell proliferation and tumor progression by affecting the mRNAs of a specific subset of genes. If any differences are found in expression of elF3m between normal and tumor tissues, this would indicate the functional importance of elF3m in tumor progression.
In this study we confirmed the expression of the uncharacterized eIF3m subunit in cancer cell lines as well as in tumor regions of human colon tissue. We also demonstrated a change in cell proliferation, cell death and cell cycle progression when eIF3m expression was silenced by specific siRNA in human colon cancer cell line HCT-116. Furthermore, we identified target genes regulated by eIF3m expression by employing a ribonomics approach, which was developed for the identification of mRNAs in mRNP complexes (Tenenbaum et al., 2002) , and confirmed that their expression is regulated in an eIF3m-dependent manner. All together, we suggest that eIF3m is involved in the regulation of tumorigenesis-related genes in human colon cancer.
Results

Elevated expression of eIF3m subunits in cancer
We first examined whether upregulation of eIF3 subunits is related to the progression of human colon tumor. For this, we performed reverse transcription real-time quantitative PCR (RT-qPCR) and measured the transcripts of 13 eIF3 subunits in pairs of normal colon and tumor (adenocarcinoma) tissues from 19 patients by relative quantification normalized by GAPDH (Supplementary Figure S1) . eIF3b was the only eIF3 core subunit that showed high expression in tumors of most of the patients (18/19). Among the eight non-core subunits, eIF3d, e, h, k and m subunits showed elevated expression in tumors of more than 50% of patients. We chose the most uncharacterized eIF3m for further study and confirmed the elevated mRNA levels of elF3m in tumors of all patients as well as in seven kinds of cultured cancer cell lines by absolute quantification deduced from a standard curve (r 2 40.95) (Figures 1a and b) . In all cancer cell lines including four colon cancer cell lines (HCT-116, SNU-C4, SNU-C5 and SNU-81), one lung cancer cell line (A549) and two breast cancer cell lines (Herceptin-resistant JIMT-1 and Herceptin-sensitive SK-BR-3), it showed more than 10-fold elevated expression level compared with the normal cell line HDF (Figure 1a) . Interestingly, JIMT-1 showed more than double the expression in SK-BR-3 ( Figure 1a ). While the relative quantification data showed higher expression in tumors of 12 out of 19 patients, the absolute quantification showed markedly elevated expression of eIF3m in tumors in all patients (paired t-test P ¼ 0.00013) (Figure 1b ). In accordance with this, cancer cell lines showed higher protein levels of eIF3m than normal cell line HDF (Figure 1c) . The difference in eIF3m protein expression between normal Figure 1 Elevated expression of eukaryotic translation initiation factor subunit, elF3m, in cancer cell lines and in human colon tumor tissues. RT-qPCR was done by absolute quantification and the copy number of eIF3m transcript per nanogram of total RNA was plotted with standard deviation from replication (n ¼ 3). (a) Absolute copy numbers of eIF3m transcript in colon cancer cell lines (HCT-116, SNU-C4, SNU-C5 and SNU-81), lung cancer cell line (A549) and breast cancer cell lines (JIMT-1 and SK-BR-3) were much higher than in normal human dermal fibroblast cell line (HDF). (b) Most of the human colon tissues showed higher expression of eIF3m in tumor than in normal counterparts. Western blotting also confirmed higher eIF3m expression in cancer cell line (c) and human colon tissues (d).
eIF3m influences tumorigenesis-related gene regulation S-H Goh et al and tumorous colon tissue was also similar, although not as dramatic as the mRNA levels ( Figure 1d ). To make sure of its expression difference, we checked its mRNA and protein levels in 20 additional paired patient tissues ( Supplementary Figures S2a and b) . Then we evaluated protein expression difference between normal and tumor tissues by densitometry (Supplementary Figure S2c ). The average density of eIF3m itself in tumor tissues was 1.3-fold higher than in its normal counterpart (paired t-test P ¼ 0.00098). The fold change of normalized density by b-actin was also 1.3 (P ¼ 0.00070). These analyses suggest that elevated expression of eIF3m is associated with tumor progression in cell lines as well as in colon tissues.
Tissue specificity of eIF3m mRNA expression We examined the tissue specificity of eIF3m expression at transcription level by Northern hybridization. Among the normal tissues, heart, skeletal muscle, kidney, liver, placenta and peripheral blood leukocytes showed elevated eIF3m expression, but in brain, colon, thymus, small intestine and lung there was no detectable expression of eIF3m (Figure 2a) . Among several human cancer cell lines, eIF3m expression in several leukemia cell lines, a lymphoma, a colorectal adenocarcinoma SW480 and in a lung carcinoma cell line A549 was high but was relatively low in melanoma cell line G-361 (Figure 2b ). In this hybridization no splice variant of eIF3m transcript was found.
Confirmation of the preferential expression of eIF3m in human colon carcinoma tissues To determine the region(s) of eIF3m expression on human colon tissue, we performed immunohistochemistry. We detected markedly high expression of eIF3m in colon carcinoma cells (Figures 3c and f) and in metastatic carcinoma cells in the regional lymph node (Figure 3a ). In contrast, we detected much lower signals in the adjacent non-neoplastic epithelial cells (Figure 3b and e). In terms of subcellular localization, eIF3m expression was not detected in the nucleus but was confined to the cytosol in both carcinoma and nonneoplastic epithelial cells. The metastatic colon carcinoma in liver also showed strong expression of eIF3m (Figures 3g-i) . These results suggest that eIF3m is highly expressed in the colon carcinoma cells where cell proliferation is active at a higher level than in the adjacent non-neoplastic epithelial cells.
Silencing eIF3m expression reduces proliferation of human colon cancer cells The low expression of eIF3m in the peritumoral regions confirmed by immunohistochemistry suggests that eIF3m is also involved in reactive proliferation as well as in tumor progression. To determine the effect of eIF3m expression on cell proliferation, we studied the effect of silencing eIF3m mRNA in HCT-116 colon cancer cells using siRNA. Silencing of eIF3m expression was confirmed by western blotting (Figure 4a and Supplementary Figure S3a ). eIF3m expression was reduced from 24 h after siRNA transfection until 96 h. In contrast, buffer only (BF) or negative control (NC) did not change the level of eIF3m protein. The confluency after BF and NC rapidly increased and reached a plateau by 72 h (Figure 4b ). In contrast, eIF3m siRNA-1 slowed down the proliferation from 24 h and kept lower confluency until 96 h (Figure 4b ). MTT assays confirmed this by showing not more than threefold increase with eIF3m siRNA-1 at 72 h compared with sixfold with NC and fivefold with BF ( Figure 4c ). This result was confirmed again by using another siRNA, siRNA-3 (Supplementary Figure S3b) . The silencing efficacies of siRNA-1 and siRNA-3 compared with NC at 96 h were 46.4% (Student's t-test P ¼ 1.3 Â 10
À5
) and 65.3% (Student's t-test P ¼ 2.8 Â 10 À9 ), respectively. These results eIF3m silencing leads to death of human colon cancer cells In the context of the cell proliferation retardation by eIF3m silencing, we analyzed cell cycle progression following eIF3m knockdown in HCT-116 cell lines by flow cytometry. The HCT-116 cells were treated with eIF3m siRNA-1, siRNA-3, BF, or NC controls. At 24 h of siRNA transfection, there was no significant difference in the proportion of each mitosis stage after treatment with NC, BF or eIF3m siRNA-1 or -3 ( Figure 5 and Supplementary Figure S4 ). As the time point moved from 24 to 96 h, the portion of sub-G0/G1 phase in eIF3m siRNA-1-treated cells increased from 1.65 to 12.36%. On the other hand, the proportion of S phase of eIF3m siRNA-1 decreased from 26.40 to 19.49%, while it increased in both BF (from 24.67 to 32.22%) and NC (from 26.00 to 30.56%). Similarly, G2/ M phase also decreased from 31.14 to 21.81%. eIF3m siRNA-3 also showed increased sub-G0/G1 (11.26%) portion compared with BF (2.52%) or NC (3.31%) and decreased G2/M-phase (19.75%) portion compared with BF (31.16%) or NC (29.22%) by 96 h. Taken together, these results suggest that silencing of eIF3m expression increased subG0/G1 proportion and led to cell death.
In agreement with this, we could confirm the effect of eIF3m silencing on cell death using several markers for apoptosis. First, it showed a steady increase of annexin V-positive cells by eIF3m siRNA-1 until 96 h ( Figure 6a ). Second, the frequency of abnormal chromosomes with condensed and/or fragmented appearance was significantly higher by eIF3m siRNA-1 (Figure 6b ). Third, PARP1, which is known for caspase substrate, almost completely turned into its activated form (89 kDa) from its inactive form (116 kDa) by eIF3m silencing compared with the slight change by NC ( Figure 6c ). Thus, eIF3m expression seems to be required for the cells to continue cell-cycle and eventually for cell proliferation.
Identification of EIF3m-associated transcripts by ribonomics
To identify a subset of genes of which expression is regulated by eIF3m, we employed a ribonomics strategy. The EIF3m open reading frame cloned into eIF3m influences tumorigenesis-related gene regulation S-H Goh et al pFLAG-CMV2 was expressed in HCT-116 cell lines. After 48 h of transfection, the tagged eIF3m was immunoprecipitated with a FLAG-M2 affinity gel. The EIF3m-inserted plasmid generated the designated size of eIF3m band on western blot, whereas blank vector control did not (Supplementary Figure S5a) . When we purified total RNA from immunoprecipitated gel pellet, the eIF3m expression clone generated the detectable amount of RNA but the blank vector did not (Supplementary Figure S5b) . This RNA was used to Figure S6) . Another class of genes noted was related to metal ionbinding activity (cadmium ion and copper ion binding). For further investigation on these transcripts we chose two highly represented genes, macrophage migration inhibitory factor (MIF) and metallothionein 2A (MT2A). They have recently been associated with tumorigenesis: MIF gene with tumor growth (Bifulco et al., 2008; Bach et al., 2009) , and MT2A gene with breast cancer (Jin et al., 2004) and chemoresistance in ovarian cancers (L' Espe´rance et al., 2006) . We examined whether the expression of MIF and MT2A is influenced by eIF3m in the HCT-116 cells. When eIF3m siRNA-1-treated HCT-116 cell lysate was examined by western blot, the protein level of MIF decreased until 48 h, as was eIF3m expression, but it was revived to the normal level from 72 h (Figure 7a ). The UC1MT antibody detects both MT1 and MT2 isoforms, but as MT2A was the major form in ribonomics, we applied the antibody to detect MT2A protein. The protein level of MT2A also decreased until 48 h, but it did not return to the normal level ( Figure 7b) unlike MIF. mRNA level estimated by RT-qPCR detected mRNA level changes ( Figure 7c ) in a similar pattern of protein level ( Figures  7a and b) . This suggests that eIF3m influences the expression of a designated subset of genes for cell proliferation and tumor progression by affecting the mRNA level. In addition, as Lim et al. (2009) reported that MT2A silencing resulted in cell division cycle 25 homolog A (CDC25A) degradation and G1-arrest in breast cancer cells, we found that eIF3m silencing immediately decreased CDC25A from 24 h until 72 h (Figure 8 ). These results further support that eIF3m expression influences the cell cycle regulation.
Discussion
Abnormal cell proliferation and cell cycle progression are hallmarks of aggressive malignant neoplasm, and upregulated protein synthesis is important to the etiology of cancer (Rosenwald, 2004) . Recent reports confirmed the importance of eIF3s in regulation of translation initiation rate and in the oncogenic roles of several of its subunits (Dong and Zhang, 2006; Zhang , 2007, 2008) . As the last defined eIF3 subunit, the function of eIF3m in humans is not yet characterized. If any differences are found in expression of elF3m between normal and tumor tissues, this would indicate the functional importance of elF3m in tumor progression. Our assessment of mRNA levels of elF3 subunits by RT-qPCR showed elevated eIF3m expression in cancer cell lines and in colon adenocarcinoma tissues. The expression difference at protein level was also detected by western blotting. These correlations suggest that elevated expression of eIF3m is an attribute of tumor tissues and/or proliferating cancer cell lines. It was reported that eIF3e in its truncated form leads to persistent hyperplasia and tumorigenesis in mammary alveolar epithelium (Mack et al, 2007) and subunits of eIF3 also showed oncogencity when modified by truncation or phosphorylation. However, in this study we could not detect any variant of eIF3m mRNA that could be considered as truncated. Also, no alternatively spliced forms of transcript was found in either normal tissues or in cancer cell lines, though its expression levels, observed in Northern blot, were different among normal tissues. The high expression of eIF3m was not restricted to the colon cancer cell line but also occurred in several leukemias and carcinomas. This suggests potential role of eIF3m in tumorigenesis in general. This study also demonstrated a low level of eIF3m expression in the normal cell line, HDF, and in the normal counterparts of tumor samples. This raises the following questions: Is eIF3m preferentially highly expressed only in tumor cells? If it is also expressed in normal cells, does it depend on the physiological state of the cell such as cell proliferation? To address these questions, we performed immunohistochemistry on several human colon tumor tissues. The tumor region showed vivid eIF3m expression compared with the peritumoral region. We also found recognizable expression of eIF3m in some other regions, for example, in the lining of colon lumen. These regions are not of the tumor itself, but are places where reactive proliferation occurs and mammalian intestinal mucosa undergoes a process of continual cell turnover essential for maintenance of normal function by epithelial restitution with migration, proliferation and differentiation of epithelial cells to form new crypts (Ramachandran et al., 2000; Humphries and Wright, 2008) . These results therefore indicate that eIF3m expression is required more for reactive proliferation of normal cells in response to inflammation and for proliferation of tumors, than for non-proliferating normal cells.
eIF3m's involvement in cell proliferation was confirmed by silencing its expression with siRNA in human colon cancer cell line HCT-116. This retarded the progression into G0/G1 phase and the fraction of cells in subG0/G1 phase increased as the time of siRNA treatment increased. In accordance with the reduction of cell proliferation, it confirmed the increase of apoptotic cells by increase in the number of annexin-V-positive cells, fragmented/condensed chromosomes and activated PARP1 protein when eIF3m expression was silenced. This implies that lack of eIF3m leads to the apoptosis of proliferating cells.
As the overexpression of eIF4E Raught and Gingras, 1999 ) and eIF4G (FukuchiShimogori et al., 1997; Pyronnet et al., 1999; LeFebvre et al., 2006) was reported to be responsible for their oncogencity, it was reported that five subunits of elF3 lead to the oncogenic properties of NIH-3T3 cells (Zhang et al., 2007) . Thus, eIF3m may also influence a subset of oncogenic genes by mediating interaction with ribosomal machinery or by regulating mRNA level. We Frequency of aberrant chromosome in NC remained around 11% but it was over 41% in eIF3m siRNA-treated cells. The significance of difference was assessed by Student's t-test and P-value was below 0.001. (c) PARP1 was detected by western blotting. PARP1 is a main cleavage target of caspase-3 and it gives out 89 kDa cleaved form from its 116 kDa full-length form. Compared with the slight increase of PARP1 in NC, almost complete activation of PARP1 was observed from 72 h in eIF3m siRNA-1 condition. eIF3m influences tumorigenesis-related gene regulation S-H Goh et al applied ribonomics strategy to address this question. Most of the genes identified from this approach were for protein translation itself (Table 1) . However, there were also many genes involved in tumor progression, such as FXYD5 (FXYD domain containing ion transport regulator 5) (Ino et al., 2002; Nam et al., 2007) , PTTG1 (pituitary tumor transforming gene 1) (Dominguez et al., 1998) and S100A6 (S100 calcium binding protein A6) (Komatsu et al., 2002) . Thus, the eIF3m-associated mRNA subset influences the expression of genes required for accelerated cell proliferation, transformation of cells and for their journey from their anchored position into other places. This concept, obviously, should be confirmed by further studies. We also evaluated the eIF3m expression-dependent regulation of MT2A and MIF, which were also identified from ribonomics by silencing eIF3m. MIF is a highly conserved multipotential protein that acts variously as a pro-inflammatory cytokine, a pituitary hormone, and as a cell proliferation and migration factor (Bifulco et al., 2008) . It is a unique cytokine affecting multiple processes fundamental to tumorigenesis (Bach et al., 2009 ). In addition, MIF has prognostic value in human colorectal cancer because its expression correlates with aggressiveness of the cancer (Legendre et al. 2003) . MT2A gene belongs to the metallothionein families, which are important for metal ion homeostasis. It was reported to be associated with breast cancer (Jin et al., 2002) and tumor grade (Jin et al., 2004) and is related to the chemoresistance of ovarian cancer (L' Espe´rance et al., 2006) . The protein level of these genes affected by silencing eIF3m and their mRNA level also changed in a similar pattern (Figure 7 ). This suggests that eIF3m expression has an effect in regulating mRNA levels of a specific subset of genes associated with cell proliferation and tumor progression. Further support for this hypothesis is provided by the reduced expression of MT2A resulting from ubiquitindependent degradation of CDC25A, which is necessary for the progression from G1 to S phase of the cell cycle via ATM/Chk2 in a breast cancer model (Lim et al., 2009) . Although HCT-116 colon cancer cells showed subG0/G1 arrest rather than G1 arrest and S phase reduction with CDC25A loss as it was reported (Tomko et al., 2009) , we supposed that this difference came from the different cell property of HCT-116 from breast cancer cells, MCF-7 or MCF12. Based on our findings, eIF3m expression may affect cell cycle progression through the regulation of MT2A level (Figure 7b ) and its downstream pathway molecule, CDC25A (Figure 8 ).
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In summary, we confirmed that eIF3m expression is elevated in proliferating cells and human colon tumor tissues. By silencing of eIF3m expression, we showed that eIF3m affects cell proliferation, cell cycle progression and cell death in colon cancer cells. To identify the eIF3m-associated gene subset, we applied ribonomics approach for the first time to the study of mammalian eukaryotic translation initiation factor and found that many of them are involved in cell proliferation and transformation. We confirmed that two highly represented tumorigenesis-related genes from this subset, MIF and MT2, are regulated by eIF3m at the mRNA level. It was shown that eIF3m eventually influences MT2A downstream molecule CDC25A, which is necessary for cell cycle progression.
The importance of eukaryotic translation initiation factors in cancer development is increasing more and eIF3m influences tumorigenesis-related gene regulation S-H Goh et al more. Further investigations on the effect of regulation of tumorigenesis-related genes by eukaryotic translation initiation factor subunits, similar to eIF3m, on human cancers will provide clues for identifying potential therapeutic targets in human cancer.
Materials and methods
Human tissues
Human colonic tissues were obtained by surgical resection from consenting patients in accordance with the protocols and guidelines approved by the Institutional Review Board and the principles of Helsinki. 
Cell culture
Western blotting
Cell and tissue lysates were prepared with protease inhibitorsupplemented mammalian protein extraction reagent or tissue protein extraction reagent lysis buffer (Thermo Scientific, Rockford, IL, USA). The lysates resolved on 4-12% NuPAGE gel (Invitrogen) were transferred onto Immobilon-P membrane (Millipore, Billerica, MA, USA). They were detected with the following antibodies for each condition: antieIF3m (1:2000, #11423-1-AP, Proteintech Group, Chicago, IL, USA); anti-MIF (2a10-4d3) (1:500, #H00004282-M01, Abnova, Taiwan); anti-metallothionein monoclonal antibody (UC1MT), which detects all metallothionein isoforms (1:500, #ab12228, Abcam, Cambridge, UK); anti-CDC25A (1:1,000, #3652, Cell Signaling, Danvers, MA, USA); and finally 1:10 000 diluted HRP-conjugated secondary antibody (Sigma-Aldrich, St Louis, MO, USA). The signal density of the region of interest was measured with background subtraction using Multi Gauge V3.0 (Fujifilm, Tokyo, Japan).
Immunohistochemistry
Human tumor tissues were fixed in 10% neutral buffered formalin solution and subjected to the standard procedure to make paraffin blocks. Slide-mounted 4-mm-thick tissues were pre-treated with proteinase and then stained by a BechMark XT automated system (Ventana Medical System, Tucson, AZ, USA). Anti-eIF3m antibody (#11423-1-AP, Proteintech Group, Chicago, IL, USA) was applied at 1:100 dilutions and the signal eIF3m influences tumorigenesis-related gene regulation S-H Goh et al was detected by biotinylated secondary antibodies, followed by the binding of streptavidin-HRP conjugate.
Silencing of eIF3m expression
The effects of eIF3m on cell proliferation and cell cycle were assayed after treatment with eIF3m-specific siRNA (#1: S10043164 5 0 -ATGGATAAGAATACTCCTGTA-3 0 ; #3: S10043178 5 0 -AAGCAAGAAGCTTTGATTGAA-3 0 , Qiagen). Two million HCT-116 cells transfected with eIF3m siRNA, or negative control siRNA NC or BF, were cultured for 96 h in a six-well plate and checked every 24 h.
Cell proliferation and cell cycle analyses Proliferation was assessed by MTT assay. Cell cycle progression was analyzed in the same manner with approximately 5 Â 10 4 HCT-116 cells stained in propidium iodide staining buffer (10 mg/ml DNase-free RNase A, 50 mg/ml propidium iodide in phosphate buffered saline) by BD Cellquest software on FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA).
Analyses of apoptosis
The reaction to detect apoptotic cells based on plasma membrane degradation was performed using FITC Annexin V apoptosis detection kit (BD Pharmingen, San Diego, CA, USA; #556 547) according to the manufacturer's protocol and then analyzed on FACSCalibur Flow Cytometer (BD Bioscience). For the observation of chromosome condensation and fragmentation, cells were fixed with 4% paraformaldehyde in 1 Â phosphate buffered saline for 20 min at room temperature and chromosomes stained with Hoechst 33342 were observed under a microscope with UV laser (detection at 480 nm). The activated form of poly (ADP-ribose) polymerase (PARP1) by caspase cleavage was detected using anti-PARP1 (1:1,000, #9542, Cell Signaling) antibody.
Ribonomics
The eIF3m open reading frame was amplified with forward (5 0 -CACCATGAGGGTCCCGGC-3 0 ) and reverse (5 0 -GGT ATCAGAAAGACTCAAAAGGCTG-3 0 ) primers and cloned into pFLAG-CMV2 (Sigma-Aldrich). Two million HCT-116 cells transfected with 4 mg of pFLAG-CMV2-eIF3m by Lipofectamine 2000 (Invitrogen) were cultured for 48 h at 37 1C. The cells were homogenized in Symplekin immunoprecipitation buffer (Kim and Richter, 2006) and cleared lysate was precipitated with 40 ml of FLAG-M2 affinity gel (SigmaAldrich). Total RNA was purified from immunoprecipitated gel pellet by Trizol reagent. In all, 1.575 mg of total RNA was used for making cDNA library by GeneRacer kit (Invitrogen) and amplification by 25 cycles of PCR with adapter primers. The PCR product was cloned into pBlueScriptII-KS( þ ) vector (Stratagene, La Jolla, CA, USA) and transformed DH10B competent cells (Invitrogen). Nucleotide sequences from randomly chosen colonies were searched against NCBI GenBank, DAVID Bioinformatics Resource (Huang et al., 2009) and SOURCE search (http://source.stanford.edu).
Assessment of statistical significance
The statistical significance was analyzed by Student's twotailed t-test for comparison between unpaired groups and Student's paired two-tailed t-test for comparison between normal/tumor tissue pairs. For displaying the error range, we adopt standard deviation or standard error mean (s.e.m.) for each group.
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